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INTRODUCTION
Long-term peritoneal dialysis (PD) is associated with pro-
gressive increase in the thickness of peritoneal membrane,
predominantly in the submesothelial compact collagenous
zone (1), and membrane hyperpermeability (2). The mecha-
nisms involved in these structural and functional changes
remain unclear, but prolonged exposure of the membrane to
conventional PD solution containing high concentrations of
glucose and glucose degradation products (GDP) may play
an important role. Epithelial-mesenchymal transition (EMT)
of epithelial cells, characterized by loss of epithelial cell char-
acteristics and gain of ECM-producing myofibroblast char-
acteristics, is an important mechanism involved in tissue fibro-
sis (3-6). Recent data (7-9) suggest that human peritoneal
mesothelial cells (HPMC) undergo EMT during PD and that
EMT may play an important role in the development and pro-
gression of peritoneal fibrosis leading to failure of peritoneal
membrane function. This brief review will discuss the mech-
anisms of EMT and suggest strategies for the prevention of
EMT and preservation of peritoneum during long-term PD. 
EMT AND PERITONEAL FIBROSIS 
Accumulating evidence implicates EMT as a potential
mechanism for the development and progression of perito-
neal fibrosis during long-term PD leading to failure of peri-
toneal membrane function. Yanez-Mo et al. (7) first report-
ed that peritoneal mesothelial cells undergo a transition from
an epithelial phenotype to a mesenchymal phenotype soon
after PD was initiated with a decrease in the expression of
cytokeratin and E-cadherin through induction of the tran-
scriptional repressor Snail. Margetts et al. (8) demonstrated
that intra-peritoneal administration of adenovirus-mediated
transforming growth factor- 1 (TGF- 1) increases peritoneal
expression of genes associated with fibrosis and EMT includ-
ing collagen I,  -smooth muscle actin ( -SMA), and Snail,
suggesting that EMT occurs in vivo after TGF- 1 overex-
pression in the peritoneum. Nonepithelioid mesothelial cells
from spent dialysate produces a greater amount of VEGF ex
vivo than epithelioid-like mesothelial cells (9), suggesting
that EMT may also have a role in peritoneal hyperperme-
ability. It is therefore important to clearly understand the
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A growing body of evidence indicates that epithelial-mesenchymal transition (EMT)
of human peritoneal mesothelial cells (HPMC) may play an important role in the
development and progression of peritoneal fibrosis during long-term peritoneal
dialysis (PD) leading to failure of peritoneal membrane function. Here, we review
our own observations and those of others on the mechanisms of EMT of HPMC
and suggest potential therapeutic strategies to prevent EMT and peritoneal fibro-
sis during long-term PD. We found that high glucose and H2O2 as well as trans-
forming growth factor- 1 (TGF- 1) induced EMT in HPMC and that high glucose-
induced EMT was blocked not only by inhibition of TGF- 1 but also by antioxidants
or inhibitors of mitogen-activated protein kinases (MAPK). Since MAPKs are down-
stream target molecules of reactive oxygen species (ROS), these data suggest
that high glucose-induced generation of ROS and subsequent MAPK activation
mediate high glucose-induced EMT in HPMC. We and others also observed that
bone morphogenetic protein-7 (BMP-7) prevented EMT in HPMC. Glucose degra-
dation products (GDP) were shown to play a role in inducing EMT. Involvement of
a mammalian target of rapamycin (mTOR) in TGF- 1-induced EMT has also been
proposed in cultured HPMC. A better understanding of the precise mechanisms
involved in EMT of HPMC may provide new therapeutic strategies for inhibiting
peritoneal fibrosis in long-term PD patients.
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mechanisms involved in EMT during PD in order to pro-
vide a novel therapeutic strategy to prevent EMT and peri-
toneal fibrosis.
MECHANISMS INVOLVED IN EMT OF HPMC
DURING PD
We have shown that high glucose (10) and glucose-based
PD solution (11) induce generation of reactive oxygen species
(ROS) in cultured HPMC and that ROS generated by glu-
cose-based conventional PD solution is responsible for peri-
toneal neoangiogenesis, membrane hyperpermeability, and
peritoneal fibrosis in rats treated with glucose-based PD solu-
tions (12). We (13) recently reported that 1) high D-glucose,
H2O2, and glucose-based PD solutions upregulate  -SMA
and downregluate E-cadherin in HPMC, 2) antioxidants,
N-acetylcystein (NAC) and catalase, effectively reverse high
glucose-induced  -SMA and E-cadherin expression in HPMC,
and that 3) prolonged exposure of rat peritoneum to glucose-
based PD solution upregulates  -SMA expression in the peri-
toneum, which is effectively inhibited by NAC. All these
data suggest that ROS plays a major role in peritoneal EMT
induced by high glucose and glucose-based PD solutions.
This is consistent with our previous observation that ROS is
involved in TGF- 1-induced EMT in renal tubular epithe-
lial cells (14). 
GDP have been suggested to play a role in inducing EMT.
Spent dialysate obtained at 12 months after the initiation of
PD using solutions containing low GDP had a significantly
fewer number of fibroblast-dominant cells compared to efflu-
ent obtained from patients using PD solutions containing
high GDP (15). Given that GDP signal through ROS (16),
it is conceivable that ROS mediate GDP-induced EMT in
the peritoneum. 
Rapamycin was shown to effectively inhibit TGF- 1-in-
duced EMT in cultured HPMC, suggesting the involvement
of a mammalian target of rapamycin (mTOR) in EMT (17).
The phosphatidylinositol 3-kinase (PI3-K)/Akt/mTOR path-
way has recently been recognized as an important pathway
in diabetic renal injury. High glucose activates the Akt/mTOR
pathway in mesangial cells (18), both Akt and mTOR are
increased in diabetic kidneys (19), and low-dose rapamycin
slows the progression of diabetic renal injury including  -
SMA overexpression and matrix accumulation (20). 
STRAGEGIES FOR PREVENTING EMT 
DURING PD
In cultured HPMC, treatment with antioxidants effecti-
vely inhibited high glucose-induced ROS generation (10)
and EMT (13). In an animal model of PD, intraperitoneal
administration of NAC effectively prevented  -SMA expres-
sion in the peritoneum (13) as well as peritoneal membrane
thickening, neoangiogenesis, and hyperpermeability (12).
These observations strongly suggest that ROS is an impor-
tant therapeutic target in peritoneal EMT and structural and
functional alterations in peritoneum during long-term PD. 
Since TGF- 1 is the major inducer of EMT, strategies
inhibiting TGF- 1 signaling is a plausible way to prevent
EMT during PD. Bone morphogenetic protein-7 (BMP-7),
a 35 kDa homodimeric protein and a member of TGF-
superfamily, is an endogenous antifibrotic protein that pre-
vents renal fibrosis in ureteral obstruction (21), diabetic ne-
phropathy (22), and nephrotoxic serum nephritis (23). We
(24) recently observed that HPMC constitutively express
BMP-7, that high glucose, glucose-based PD solution, and
TGF- 1 downregulated BMP-7 expression in HPMC, and
that overexpression of BMP-7 in HPMC prevented EMT
induced by TGF- 1, suggesting BMP-7 as a potential thera-
peutic strategy for preventing EMT of HPMC. This is con-
sistent with a recent report (25) that ex vivo treatment with
BMP-7 reversed in vivo and ex vivo EMT of HPMC. BMP-
7 significantly inhibited TGF- 1-induced phosphoylation
of Smad 2/3 and MAPKs in HPMC (24). 
Rapamycin can prevent TGF- 1-induced EMT in HPMC
(17) presumably through inhibition of high glucose-induced
activation of the mTOR pathway (18). 
Clinical trials are needed to prove the efficacy of these ex-
perimental strategies in PD patients.
CONCLUSION
Cell culture and animal studies suggest that high glucose,
GDP, glucose-based PD solution, TGF- 1, loss of BMP-7,
and activation of the mTOR pathway induce EMT of HPMC
and that antioxidants, BMP-7, and rapamycin may prevent
EMT and allow better preservation of structural and func-
tional integrity of the peritoneal membrane during long-
term PD. Further studies elucidating the mechanisms involv-
ed in EMT of HPMC and clinical trials may provide new
therapeutic strategies for inhibiting peritoneal fibrosis dur-
ing long-term PD.
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